RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

<div>Forrest plot of hazard ratios for DFS of the surgical resection patients. Except for vascular tumor thrombus, none of the other clinicopathologic features showed significant association with poorer DFS.</div>

Canadian Journal of Gastroenterology and Hepatology

fig3

Figure 3

Figure 3: RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients 